Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7

You may also be interested in...



SFDA Proposes New Review Channel For Innovative Drugs

Pressured by increasing calls from industry, China’s State FDA released a new proposal to expedite new drug reviews, focusing on drugs with high clinical value.

Outlier: Takeda Scores Chinese Clinical Trial Authorization For Diabetes Agent In Record 7 Months

It’s not an anticancer therapy, and it has only Phase II data from overseas, but Takeda has managed to cut the average clinical trial authorization time for Class 1 new drugs in China by two months.

Lost In Reimbursement? Innovative Drugs Encounter Lengthy Delays In China – IMS Study

A market access study conducted by IMS and RDPAC sheds lights on regulatory and reimbursement challenges facing MNCs in China.

Related Content

UsernamePublicRestriction

Register

SC069768

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel